Volanesorsen

DB15067

biotech approved investigational

Deskripsi

Volanesorsen is an antisense oligonucleotide that binds to apoC-III mRNA to prevent its translation.^L16621 It is indicated to treat familial chylomicronemia, a genetic condition that prevents breakdown of triglycerides and chylomicrons.^L16621 This drug is not commonly prescribed as it is used as an adjunct to diet in patients at high risk for pancreatitis, who have had inadequate response to triglyceride lowering therapy.^L16621

Volanesorsen was granted a conditional approval by the European Medicines Agency.^L16621

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler

Obat Target Gen Interaksi Enzim Transporter Carrier

Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

1. Pendahuluan & Konsep

Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).

2. Sumber Data (Validasi)

Data Obat: Diekstraksi dari elemen drugbank-id dan name pada skema XML DrugBank.
Target Protein: Diambil dari elemen targets/target yang memuat polipeptida sasaran.
Genetik: Disinkronisasi dari sub-elemen gene-name dan varian snp-effects.
Genetik: Jumlah titik node dibatasi pada maksimal 10 (Slice=10) interaksi untuk menghindari tumpukan data.

3. Algoritma Visualisasi

Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.

4. Legenda Visual

Obat Utama (Pusat Analisis)

Target Protein (Mekanisme)

Gen (Faktor Genetik)

Metode ini mendukung analisis Precision Medicine dan evaluasi risiko Drug-Drug Interaction (DDI).

Profil Farmakokinetik

Waktu Paruh (Half-Life) Volanesorsen has a half life of >2 weeks.[L16621]

Volume Distribusi The volume of distribution at steady state is 330 L in patients with familial chylomicronemia.[L16621]

Klirens (Clearance) The exact rate of clearance of volanesorsen is unknown, however it is rapidly distributed to tissues and very slowly eliminated.[L16621]

Absorpsi

Volanesorsen is approximately 80% bioavailable.^L16621 A 285mg dose given weekly reaches a C_max of 8.92 µg/mL, with an AUC of 136 µg\*h/mL.^L16621

Metabolisme

Volanesorsen is metabolized by endonucleases and exonucleases in a nonspecific manner.^L16621 The unchanged parent drug is 26% recovered in the urine and pentamer to heptamer sized metabolites account for 55% of urinary recovery.[L16621

Rute Eliminasi

Volanesorsen is predominantly eliminated in the urine, though <3% of a dose was recovered within 24 hours.^L16621

Interaksi Obat

0 Data

Tidak ada data.

Target Protein

Apolipoprotein C-III APOC3

Referensi & Sumber

Artikel (PubMed)

PMID: 31350288
Post N, Yu R, Greenlee S, Gaus H, Hurh E, Matson J, Wang Y: Metabolism and Disposition of Volanesorsen, a 2'-O-(2 methoxyethyl) Antisense Oligonucleotide, Across Species. Drug Metab Dispos. 2019 Oct;47(10):1164-1173. doi: 10.1124/dmd.119.087395. Epub 2019 Jul 26.

Link

EMA Summary of Product Characteristics: Waylivra Volanesorsen Subcutaneous Injection

Contoh Produk & Brand

Produk: 3 • International brands: 1

Produk

Na

Powder • 1 kg/1kg • - • US
Waylivra

Injection, solution • 285 mg • Subcutaneous • EU • Approved
Waylivra

Injection, solution • 285 mg • Subcutaneous • EU • Approved

International Brands

Waylivra

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.

Peringatan Keamanan